Optimizing Outcomes in Myasthenia Gravis Through Personalized Care and Treatment Selection

Expert neurologists discuss the presentation of myasthenia gravis (MG), focusing on the variability of symptoms from patient to patient.

Experts in neurology comment on fatigue and fluctuation of symptoms in MG and how that can contribute to a delay in diagnosis.

Beth Stein, MD, reviews critical steps towards diagnosing MG, taking a look at the different types of reliable testing for the disease.

Ali Habib, MD, comments on the prevalence of MG in older patients and the increasing rate of hospitalization and mortality within this group.

Expert neurologists discuss the factors that guide treatment selection in MG, shifting the framework to take patient preferences into account.

Experts in neurology highlight taking age and quality of life into consideration when approaching treatment of MG, as well as comment on the standard of care for patients.

Nicholas Silvestri, MD, FAAN, and Tuan Vu, MD, provide an overview of the current FDA-approved targeted therapies for the treatment of MG.

Expert neurologists discuss the treatment algorithm of MG, focusing on the use of targeted therapies as well as barriers to their use.

Experts in neurology review the varied routes of administration of targeted treatment in MG, highlighting intravenous and subcutaneous formulations and how they can provide more patient-centric care.

Expert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.

Experts in neurology discuss how to ensure disease progression in not due to poor adherence to treatment in MG, emphasizing educating the patient about their disease.

Neurology experts provide an overview of emerging treatments in MG, highlighting biomarkers and new routes of administration.